Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

How Richmond Pharmacology Supports Sponsors Navigating ICH E6 (R3)

5
February 2026

The updated ICH E6 (R3) guideline places greater emphasis on proportionality, risk-based oversight...

View Article

Accelerated Pathways: How ILAP Gives Developers a Strategic Early Advantage

29
January 2026

The pace of medical innovation is faster than ever, but patients often face delays in accessing transformative therapies.

View Article

Leadership Spotlight-  Head of Clinical Operations

20
January 2026

We are pleased to introduce Leadership Spotlight, a feature that shares insight into the leaders behind our teams and the work they deliver across Richmond.

View Article

Regulatory Pathways to Success

9
January 2026

Structured pathways to accelerate development and approval.

View Article

Participant-Centred Recruitment and Retention: Driving Faster Answers in Clinical Trials.

18
December 2025

Richmond Pharmacology is proud to announce the publication of an editorial by Elizabeth Romano, Director of Communications and Participant Engagement, in the Winter 2025 issue of the Journal for Clinical Studies.

View Article

Five Years Since a World-First CRISPR Breakthrough at Richmond Pharmacology

8
December 2025

In November 2020, Richmond Pharmacology made medical history when a patient received the first-ever systemically delivered CRISPR therapy, using lipid nanoparticles to edit genes directly inside the human body.

View Article

Latest news

How Richmond Pharmacology Supports Sponsors Navigating ICH E6 (R3)

February 5, 2026
The updated ICH E6 (R3) guideline places greater emphasis on proportionality, risk-based oversight...
Read more

Events

Clinical Trials Innovation Programme

10 - 11 February 2026
Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.
View event